Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy

Archives of Neurology

Volumn 66, Issue 2, 2009, Pages 255-258

  Cettomai, Deanna ^a   McArthur, Justin C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; MIRTAZAPINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; DYSARTHRIA; EVENING DOSAGE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAGNETISM; MALE; NEUROLOGIC EXAMINATION; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROPHYLAXIS; SIDE EFFECT; TREATMENT WITHDRAWAL; WEAKNESS; WEIGHT GAIN;

ADULT; BLOOD-BRAIN BARRIER; BRAIN; DRUG ADMINISTRATION SCHEDULE; EARLY DIAGNOSIS; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MIANSERIN; MIDDLE AGED; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 60549087519     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2008.557     Document Type: Article

References (13)

1. Santagata S, Kinney HC. Mechanism of JCV entry into oligodendrocytes. Science. 2005;309(5733):381-382.
2. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy: the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 1992; 5(1):49-73.
3. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354(9):924-933.
4. Roberts MT. AIDS-associated progressive multifocal leukoencephalopathy: current management strategies. CNS Drugs. 2005;19(8):671-682.
5. Antinori A, Cingolani A, Lorenzini P, et al; Italian Registry Investigative Neuro AIDS Study Group. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol. 2003;9 (suppl 1):47-53.
6. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380- 1383.
7. Altschuler EL, Kast RE. The atypical antipsychotic agents zisprasidone, risperidone, and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses. 2005;65(3):585-586.
8. Szegedi A, Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert Opin Pharmacother. 2005;6(4):631-641.
9. Huang SS, Skolasky RL, Dan Pan GJ, Royal W 3rd, McArthur JC. Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol. 1998;4(3):324-332.
10. Vulliemoz S, Lurati-Ruiz F, Borruat FX, et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry. 2006;77(9):1079-1082.
11. Owczarczyk K, Hilker R, Brunn A, Hallek M, Rubbert A. Progressive multifocal leukoencephalopathy in a patient with sarcoidosis: successful treatment with ci-dofovir and mirtazapine. Rheumatology (Oxford). 2007;46(5):888-890.
12. Verma S, Cikurel K, Koralnik I, et al. Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis. 2007;196(5):709-711.
13. Elliott AJ, Roy-Byrne PP. Mirtazapine for depression in patients with human immunodeficiency virus. J Clin Psychopharmacol. 2000;20(2):265-267.